Novel Potent 5-HT<sub>1F</sub> Receptor Agonists: Structure−Activity Studies of a Series of Substituted <i>N</i>-[3-(1-Methyl-4-piperidinyl)-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-5-yl]amides
作者:Sandra A. Filla、Brian M. Mathes、Kirk W. Johnson、Lee A. Phebus、Marlene L. Cohen、David L. Nelson、John M. Zgombick、Jon A. Erickson、Kathryn W. Schenck、David B. Wainscott、Theresa A. Branchek、John M. Schaus
DOI:10.1021/jm030020m
日期:2003.7.1
Compound 1a (LY334370), a selective 5-HT1F receptor agonist (SSOFRA), inhibited dural inflammation in the neurogenic plasma protein extravasation model of migraine and demonstrated clinical efficacy for the acute treatment of migraine. Although 1 was greater than 100-fold selective over both the 5-HT1B and 5-HT1D receptors, it exhibited appreciable 5-HT1A receptor affinity. Described here is the synthesis and evaluation of a series of pyrrolo[2,3-c]pyridine and pyrrolo[3,2-b]pyridine (2a and 3a) as well as pyrrolo[3,2-d]pyrimidine (4a) analogues of 1, compounds prepared in an effort to identify SSOFRAs with improved selectivity over other 5-HT1 receptor subtypes. The pyrrolo [3,2-b] pyridine analogue 3a showed high 5-HT1F receptor affinity but offered no improvement in selectivity compared to 1. However, the C-5 acetamide derivative, 3b, was greater than 100-fold selective over the 5-HT1A, 5-HT1B, and 5-HT1D receptors. SAR studies of this series determined that alkylamides in particular exhibited high selectivity for the 5-HT1F receptor. Replacement at C-5 with other substituents decreased affinity or selectivity. These SAR studies identified SSOFRAs that demonstrated oral activity in the neurogenic plasma protein extravasation model, a model indicative of antimigraine activity.